AB-1002 is an investigational gene therapy for the treatment of adults with non-ischemic cardiomyopathy and New York Heart Association (NYHA) Class III heart failure symptoms GenePHIT is a clinical ...
Have you ever wondered why we have to be inundated with so many prescription drug commercials on TV? I’m old enough to remember when there were very few, if any, ...
Legislators who favor the liability protection for Bayer say lawsuits alleging the herbicide Roundup causes cancer would hurt ...
Shares of BridgeBio Pharma (NASDAQ:BBIO), currently valued at $5.88 billion, witnessed an uptick as Scotiabank (TSX:BNS) analyst Greg Harrison increased the price target to $49 from $48 while ...
The table below is a review of notable updates that occurred in January 2025 for investigational products in development.
Bayer is committed to advancing treatment in prostate cancer care, showcasing new analyses from its comprehensive clinical trial program for NUBEQA ® (darolutamide), which includes the ARANOTE, ...
The acquisition of Anthos Therapeutics could be worth up to $3.1 billion and returns to Novartis a blood thinner it licensed ...
By Ludwig Burger and Ariane Luthi (Reuters) -Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a ...
The approval is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most rapid benefit seen in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback